Butterfly Medical Overview
Butterfly Medical is developing treatment for enlarged prostate (BPH). The Butterfly implant is designed to fit the unique anatomy of the prostatic urethra, dilate the obstructed area, and restore urine flow and quality of life. The delivery procedure takes minutes to complete and is a minimally invasive treatment. The company is conducting a clinical trial, with dozens of patients treated so far and several additional clinical trials pending. So far, the data show that the Butterfly device offers a simple, fast, and safe treatment for men with BPH symptoms.
Cumulative Funding Raised Over Time ($)
$2.0MJan 2020
$9.0MOct 2020
Latest News
growth-positive
/PRNewswire/ -- Butterfly Medical, a medical device company focused on alleviating suffering in patients with BPH (Benign Prostatic Hyperplasia), announced...
Butterfly Medical, a company specializing in medical devices for Benign Prostatic Hyperplasia (BPH), announced the presentation of new research on its prostatic retraction device at the American Urological Associations Annual Conference in April 2025. The device, which has CE Mark Approval, is minimally invasive and currently undergoing a pivotal clinical study in the U.S. It offers a reversible procedure that can be performed under local anesthesia, providing significant relief for patients. The presentations at the conference will highlight the devices long-term effectiveness, with positive outcomes observed up to five years post-treatment.
Product StageFDA approved/pending approval
growth-positive
/PRNewswire/ -- Butterfly Medical, a medical device company focused on alleviating suffering in patients with BPH (Benign Prostatic Hyperplasia), announced...
Butterfly Medical, a company focused on developing a minimally invasive treatment for Benign Prostatic Hyperplasia (BPH), has appointed Dr. James Ulchaker as Chief Medical Officer. Dr. Ulchaker will support the companys efforts toward FDA approval and U.S. commercialization of their novel implantable device, which aims to improve the quality of life for patients with BPH. The device, which has already received CE Mark Approval, is currently undergoing pivotal clinical trials in the U.S. This strategic appointment is expected to enhance Butterfly Medicals medical strategy and patient-focused care, positioning the company for growth as it seeks to address a significant healthcare challenge.
Management ChangesProduct Stage
growth-positive
Treating enlarged prostate without surgery or drugs
Butterfly Medical has developed a metal coil device to treat non-cancerous benign prostatic hyperplasia (BPH) without drugs or surgery. The device can be inserted by a urologist in a quick outpatient procedure and is reversible. Butterfly aims to provide a simpler and more efficient alternative to existing treatments like TURP and ablative technologies. The company has received European Union CE approval for its first-generation device and is conducting clinical tests for its latest device. Butterfly has raised $9 million in funding, including investments from New Rhein Healthcare Investors and the Israel Innovation Authority. The company plans to open U.S. trials in early 2021 to seek FDA approval. Butterflys co-founders have backgrounds in medical devices and the company plans to expand its product offerings in the future.
Customers
growth-positive
Prostate implant co Butterfly Medical raises $7m
Israeli medical device company Butterfly Medical has raised $7 million in a Series B financing round led by New Rhein Healthcare Investors. The company is developing a novel implantable device to treat men suffering from enlarged prostates. Butterfly Medical has completed the enrollment of 49 patients in its clinical study and the results so far are positive. The funding will be used to conduct a pivotal US clinical trial and establish US headquarters. The device aims to provide a simpler and safer alternative to existing treatments for benign prostatic hyperplasia (BPH). BPH affects a significant portion of older men and can cause urinary tract obstruction and other symptoms. Butterfly Medical aims to offer a less invasive solution for patients.
InvestmentExpand
growth-positive
Butterfly Medical Ltd., a portfolio company of Alon Med-Tech Ventures, owned by Dr. Shimon Eckhouse, completes a $2M round of financing
Israeli medical device startup Butterfly Medical has completed a $2M round of financing led by Paul Merage, Kamran Siminou, Mori Arkin, Dan Suesskind, and several other private investors. The company has developed a non-surgical implant for the treatment of enlarged prostate symptoms. The implant is delivered to the prostatic urethra in a procedure that can be done at the physicians clinic, offering a simple and safe alternative to current treatments. A clinical trial in Israel has shown good clinical outcomes and demonstrated the procedures simplicity and safety. The investors participation is seen as a vote of confidence in the company and its technology. Butterfly Medical aims to provide a non-surgical treatment option for the millions of men affected by this condition.
InvestmentExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $9M |
| Last funding | $7M |
| Stage | B |
| Rounds | 2 |
| Investors | 6 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | butterfly-medical.com |
Locations
Yokneam, Israel
Photos & Videos
4 item(s)
Butterfly Medical Business
Business models
B2B2C
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcarePatientsProvidersConsumersDemographics & FamilySeniorsCore Technology
Materials & SubstancesImplantsTags (10)
patientsdoctorsmedical-devicesminimally-invasivenon-surgicaltreatmentsclinicsmedical-productsseniorsurologyButterfly Medical Financials
$9M
Total funding
Undisclosed
Capital raised
$7M
Last funding
B
Funding stage
2
Total rounds
6
Investors
Cumulative Funding Raised Over Time ($)
$2.0MJan 2020
$9.0MOct 2020
Private Equity Funding
B Round
Oct 2020
$7M
New Rhein Healthcare Investors (Lead)
,
Mori Arkin
A Round
Jan 2020
$2M
Paul Merage (Lead)
,
Dan Suesskind, Alon MedTech Ventures, Mori Arkin, Kamran Siminou
Butterfly Medical Lifecycle
Cumulative Funding Raised Over Time
$2.0MJan 2020
$9.0MOct 2020
All Events
B Round
Oct 2020
$7M
New Rhein Healthcare Investors (Lead)
,
Mori Arkin
A Round
Jan 2020
$2M
Paul Merage (Lead)
,
Dan Suesskind, Alon MedTech Ventures, Mori Arkin, Kamran Siminou
Butterfly Medical News
7 articles
growth-positive
/PRNewswire/ -- Butterfly Medical, a medical device company focused on alleviating suffering in patients with BPH (Benign Prostatic Hyperplasia), announced...
Butterfly Medical, a company specializing in medical devices for Benign Prostatic Hyperplasia (BPH), announced the presentation of new research on its prostatic retraction device at the American Urological Associations Annual Conference in April 2025. The device, which has CE Mark Approval, is minimally invasive and currently undergoing a pivotal clinical study in the U.S. It offers a reversible procedure that can be performed under local anesthesia, providing significant relief for patients. The presentations at the conference will highlight the devices long-term effectiveness, with positive outcomes observed up to five years post-treatment.
Product StageFDA approved/pending approval
growth-positive
/PRNewswire/ -- Butterfly Medical, a medical device company focused on alleviating suffering in patients with BPH (Benign Prostatic Hyperplasia), announced...
Butterfly Medical, a company focused on developing a minimally invasive treatment for Benign Prostatic Hyperplasia (BPH), has appointed Dr. James Ulchaker as Chief Medical Officer. Dr. Ulchaker will support the companys efforts toward FDA approval and U.S. commercialization of their novel implantable device, which aims to improve the quality of life for patients with BPH. The device, which has already received CE Mark Approval, is currently undergoing pivotal clinical trials in the U.S. This strategic appointment is expected to enhance Butterfly Medicals medical strategy and patient-focused care, positioning the company for growth as it seeks to address a significant healthcare challenge.
Management ChangesProduct Stage
growth-positive
Treating enlarged prostate without surgery or drugs
Butterfly Medical has developed a metal coil device to treat non-cancerous benign prostatic hyperplasia (BPH) without drugs or surgery. The device can be inserted by a urologist in a quick outpatient procedure and is reversible. Butterfly aims to provide a simpler and more efficient alternative to existing treatments like TURP and ablative technologies. The company has received European Union CE approval for its first-generation device and is conducting clinical tests for its latest device. Butterfly has raised $9 million in funding, including investments from New Rhein Healthcare Investors and the Israel Innovation Authority. The company plans to open U.S. trials in early 2021 to seek FDA approval. Butterflys co-founders have backgrounds in medical devices and the company plans to expand its product offerings in the future.
Customers
growth-positive
Prostate implant co Butterfly Medical raises $7m
Israeli medical device company Butterfly Medical has raised $7 million in a Series B financing round led by New Rhein Healthcare Investors. The company is developing a novel implantable device to treat men suffering from enlarged prostates. Butterfly Medical has completed the enrollment of 49 patients in its clinical study and the results so far are positive. The funding will be used to conduct a pivotal US clinical trial and establish US headquarters. The device aims to provide a simpler and safer alternative to existing treatments for benign prostatic hyperplasia (BPH). BPH affects a significant portion of older men and can cause urinary tract obstruction and other symptoms. Butterfly Medical aims to offer a less invasive solution for patients.
InvestmentExpand
growth-positive
Butterfly Medical Ltd., a portfolio company of Alon Med-Tech Ventures, owned by Dr. Shimon Eckhouse, completes a $2M round of financing
Israeli medical device startup Butterfly Medical has completed a $2M round of financing led by Paul Merage, Kamran Siminou, Mori Arkin, Dan Suesskind, and several other private investors. The company has developed a non-surgical implant for the treatment of enlarged prostate symptoms. The implant is delivered to the prostatic urethra in a procedure that can be done at the physicians clinic, offering a simple and safe alternative to current treatments. A clinical trial in Israel has shown good clinical outcomes and demonstrated the procedures simplicity and safety. The investors participation is seen as a vote of confidence in the company and its technology. Butterfly Medical aims to provide a non-surgical treatment option for the millions of men affected by this condition.
InvestmentExpand
growth-positive
Butterfly Medical awarded CE Mark for prostate device
Israeli medical device company Butterfly Medical has obtained European CE Mark approval for its novel medical device for non-surgical, office-based treatment of Benign Prostate Hyperplasia (BPH). The device is designed to dilate the prostatic urethra without surgical incision or prostate tissue removal, providing a simple, fast, and minimally invasive alternative to drug treatment or surgery. The procedure can be performed in the physicians office under local anesthesia, taking less than 10 minutes. Early results from clinical trials are promising, with blocked prostates successfully opened and high patient satisfaction. Butterfly Medicals CEO mentioned that their closest competitor was sold for over $1 billion, indicating market potential.
Customers
growth-positive
UC Berkeley alumnus's startup develops mechanism to treat urinary blockage The Daily Californian
Butterfly Medical, a social impact startup, has developed a device to treat urinary blockage from noncancerous enlargement of the prostate. The company won a prize reward of $15,000 in a competition led by LAUNCH, UC Berkeleys startup accelerator. The devices design fits the specific shape of the prostate and dilates it, restricting the flow of urine. Butterfly Medicals device is made up of a unique metal called Nitinol and offers patients instantaneous relief. The company participated in the LAUNCH accelerator program, which provided guidance and funding. The program requires startup founders to interview 100 customers. Haas School of Business will hold its next Demo Day on April 27.
InvestmentCustomers
Butterfly Medical Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 20 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 12 classification IDs that could be used for matching.
Butterfly Medical Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 99/100 |
| Missing | markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 515136331 |
| Crunchbase | butterfly-medical |
| Creator | Alyssa Williams |
| Creator email | williamsar95@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wain@gmail.com |
| Last update | 2020-12-15T00:00:00.000Z |
| Created | 2015-08-02T00:00:00.000Z |
| Claimed | Yes |